Pacific Biosciences Of California (PACB) Shares Outstanding (Weighted Average) (2010 - 2026)

Pacific Biosciences Of California has reported Shares Outstanding (Weighted Average) for 17 years, with the latest figure at $305.8 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 3.02% year-over-year to $305.8 million; the trailing twelve-month figure through Mar 2026 stood at $305.8 million (up 3.02% YoY), and the FY2025 full-year result was $300.0 million, up 9.28% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $305.8 million, up from $300.0 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $305.8 million in Q1 2026, with the low at $222.3 million in Q1 2022.
• Average Shares Outstanding (Weighted Average) over 5 years is $263.8 million, with a median of $269.6 million recorded in 2024.
• Year-over-year, Shares Outstanding (Weighted Average) surged 1907.35% in 2022 and grew 3.02% in 2026.
• Tracing PACB's Shares Outstanding (Weighted Average) over 5 years: stood at $224.6 million in 2022, then advanced by 12.95% to $253.6 million in 2023, then advanced by 8.22% to $274.5 million in 2024, then gained by 9.28% to $300.0 million in 2025, then climbed by 1.95% to $305.8 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $305.8 million (Q1 2026), $300.0 million (Q4 2025), and $299.3 million (Q3 2025), per Business Quant data.

Peer Comparison